The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.

In this trial (KEYNOTE-427), treatment of patients with advanced non-clear cell renal cell carcinoma (RCC) with pembrolizumab monotherapy demonstrated an overall objective response rate of around 25% for papillary RCC patients and almost 35% for patients with unclassified RCC.

Pembrolizumab is currently only available for the treatment of advanced kidney cancer through taking part in a clinical trial. It is yet to be approved for use within the UK and the NHS by the MHRA and NICE respectively.

Read more in Cancer Therapy Advisor here

Read more in Renal & Urology News here